Author:
Soledad Poetto Ariana,Posocco Bianca,Zanchetta Martina,Gagno Sara,Orleni Marco,Canil Giovanni,Alberti Martina,Puglisi Fabio,Toffoli Giuseppe
Subject
Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry
Reference23 articles.
1. Abemaciclib: the newest CDK4/6 Inhibitor for the treatment of breast cancer;Palumbo;Ann. Pharmacother.,2019
2. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: a network meta-analysis;Desnoyers;Cancer Treat. Rev.,2020
3. FDA, Center for Drug Evaluation and Research, Highlights of prescribing information regarding Verzenio (Abemaciclib), n.d. www.fda.gov/medwatch. (accessed February 5, 2022).
4. EMA, EMA Abemaciclib Summary of Product CharachteristicsS, (n.d.).
5. FDA, Verzenio (abemaciclib) Multi-disciplinary Review and Evaluation - Reference ID: 4159723, n.d. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208716Orig1s000MultidisciplineR.pdf (accessed February 5, 2022).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献